Stanley B. Cohen, MD

Rheumatologist Stanley B. Cohen from UT Southwestern Medical School offers insight on key findings in rheumatoid arthritis (RA) presented at ACR 2021. 

First, Dr Cohen discusses a series of abstracts from the ORAL Surveillance trial. The study demonstrated that the incidence of major adverse cardiovascular events and malignancies was higher with tofacitinib than with tumor necrosis factor inhibitors, but only in certain patient subgroups. Next, he highlights a series of abstracts looking at the response to COVID vaccination in patients with autoimmune diseases, primarily RA. It was observed that many RA therapies blunt the response to COVID vaccines. 

Dr Cohen then discusses a study of the ability of abatacept to delay the development of RA. The study evaluated patients who received abatacept vs placebo for 6 months and were then followed up 1 year after treatment. After 12 months, close to 40% of people on placebo developed RA vs only 8% of those on abatacept.  

He then shares insight on a study that examined whether initial response to RA therapy could predict a patient's risk for refractory RA. The study found that patients for whom initial therapy was ineffective or difficult to tolerate were more likely to develop refractory RA.  

Dr Cohen closes his commentary by discussing a study on the effectiveness of cycling JAK inhibitors in patients with RA.  

--

Clinical Professor, Department of Internal Medicine, UT Southwestern Medical School; Director, Rheumatology Training Program, THR Presbyterian, Rheumatology Associates, Dallas, Texas 

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Received research grant from: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Rheumatologist Stanley B. Cohen from UT Southwestern Medical School offers insight on key findings in rheumatoid arthritis (RA) presented at ACR 2021. 

First, Dr Cohen discusses a series of abstracts from the ORAL Surveillance trial. The study demonstrated that the incidence of major adverse cardiovascular events and malignancies was higher with tofacitinib than with tumor necrosis factor inhibitors, but only in certain patient subgroups. Next, he highlights a series of abstracts looking at the response to COVID vaccination in patients with autoimmune diseases, primarily RA. It was observed that many RA therapies blunt the response to COVID vaccines. 

Dr Cohen then discusses a study of the ability of abatacept to delay the development of RA. The study evaluated patients who received abatacept vs placebo for 6 months and were then followed up 1 year after treatment. After 12 months, close to 40% of people on placebo developed RA vs only 8% of those on abatacept.  

He then shares insight on a study that examined whether initial response to RA therapy could predict a patient's risk for refractory RA. The study found that patients for whom initial therapy was ineffective or difficult to tolerate were more likely to develop refractory RA.  

Dr Cohen closes his commentary by discussing a study on the effectiveness of cycling JAK inhibitors in patients with RA.  

--

Clinical Professor, Department of Internal Medicine, UT Southwestern Medical School; Director, Rheumatology Training Program, THR Presbyterian, Rheumatology Associates, Dallas, Texas 

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Received research grant from: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Rheumatologist Stanley B. Cohen from UT Southwestern Medical School offers insight on key findings in rheumatoid arthritis (RA) presented at ACR 2021. 

First, Dr Cohen discusses a series of abstracts from the ORAL Surveillance trial. The study demonstrated that the incidence of major adverse cardiovascular events and malignancies was higher with tofacitinib than with tumor necrosis factor inhibitors, but only in certain patient subgroups. Next, he highlights a series of abstracts looking at the response to COVID vaccination in patients with autoimmune diseases, primarily RA. It was observed that many RA therapies blunt the response to COVID vaccines. 

Dr Cohen then discusses a study of the ability of abatacept to delay the development of RA. The study evaluated patients who received abatacept vs placebo for 6 months and were then followed up 1 year after treatment. After 12 months, close to 40% of people on placebo developed RA vs only 8% of those on abatacept.  

He then shares insight on a study that examined whether initial response to RA therapy could predict a patient's risk for refractory RA. The study found that patients for whom initial therapy was ineffective or difficult to tolerate were more likely to develop refractory RA.  

Dr Cohen closes his commentary by discussing a study on the effectiveness of cycling JAK inhibitors in patients with RA.  

--

Clinical Professor, Department of Internal Medicine, UT Southwestern Medical School; Director, Rheumatology Training Program, THR Presbyterian, Rheumatology Associates, Dallas, Texas 

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships: 

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Received research grant from: Amgen; AbbVie; Pfizer; BMS; Genentech; Lilly 

Dr Stanley Cohen, of the University of Texas, Southwestern Medical School in Dallas, reviews key abstracts on the management of patients with rheumatoid arthritis (RA) that were presented at this year's American College of Rheumatology (ACR) annual meeting, held virtually because of COVID-19.

Dr Cohen highlights the updated ACR pharmacologic recommendations for the treatment of RA, including the need to maximize methotrexate therapy as well as the avoidance of glucocorticoids and their associated long-term toxicity.

Dr Cohen discusses two abstracts addressing the use of the recombinant zoster vaccine (RZV) in patients with RA, including research from Sweden comparing immunologic response in patients taking JAK inhibitors with that of patients not on disease-modifying therapy. He also reports on a safety study from the Cleveland Clinic which followed patients after they received RZV and measured their rate of flares over 3 months.

Additionally, he discusses recent trial data on the incidence of and risk for venous thromboembolism events in patients with RA enrolled in the upadacitinib phase 3 clinical trial program.

--

Stanley B. Cohen, MD, Clinical Professor, Department of Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical School; Director, Division of Rheumatology, Texas Health Resources, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships:
Received research grant from: Amgen; AbbVie; Genentech; Gilead; Pfizer; Roche.
 

Dr Stanley Cohen, of the University of Texas, Southwestern Medical School in Dallas, reviews key abstracts on the management of patients with rheumatoid arthritis (RA) that were presented at this year's American College of Rheumatology (ACR) annual meeting, held virtually because of COVID-19.

Dr Cohen highlights the updated ACR pharmacologic recommendations for the treatment of RA, including the need to maximize methotrexate therapy as well as the avoidance of glucocorticoids and their associated long-term toxicity.

Dr Cohen discusses two abstracts addressing the use of the recombinant zoster vaccine (RZV) in patients with RA, including research from Sweden comparing immunologic response in patients taking JAK inhibitors with that of patients not on disease-modifying therapy. He also reports on a safety study from the Cleveland Clinic which followed patients after they received RZV and measured their rate of flares over 3 months.

Additionally, he discusses recent trial data on the incidence of and risk for venous thromboembolism events in patients with RA enrolled in the upadacitinib phase 3 clinical trial program.

--

Stanley B. Cohen, MD, Clinical Professor, Department of Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical School; Director, Division of Rheumatology, Texas Health Resources, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships:
Received research grant from: Amgen; AbbVie; Genentech; Gilead; Pfizer; Roche.
 

Dr Stanley Cohen, of the University of Texas, Southwestern Medical School in Dallas, reviews key abstracts on the management of patients with rheumatoid arthritis (RA) that were presented at this year's American College of Rheumatology (ACR) annual meeting, held virtually because of COVID-19.

Dr Cohen highlights the updated ACR pharmacologic recommendations for the treatment of RA, including the need to maximize methotrexate therapy as well as the avoidance of glucocorticoids and their associated long-term toxicity.

Dr Cohen discusses two abstracts addressing the use of the recombinant zoster vaccine (RZV) in patients with RA, including research from Sweden comparing immunologic response in patients taking JAK inhibitors with that of patients not on disease-modifying therapy. He also reports on a safety study from the Cleveland Clinic which followed patients after they received RZV and measured their rate of flares over 3 months.

Additionally, he discusses recent trial data on the incidence of and risk for venous thromboembolism events in patients with RA enrolled in the upadacitinib phase 3 clinical trial program.

--

Stanley B. Cohen, MD, Clinical Professor, Department of Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical School; Director, Division of Rheumatology, Texas Health Resources, Texas Health Presbyterian Hospital Dallas, Dallas, Texas.

Stanley B. Cohen, MD, has disclosed the following relevant financial relationships:
Received research grant from: Amgen; AbbVie; Genentech; Gilead; Pfizer; Roche.